Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERSANA THERAPEUTICS, INC.

(MRSN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
9(c) 9.71(c) 9.89(c) 9.48(c) 9.59(c) Last
1 568 161 813 805 1 538 573 487 011 309 112 Volume
0.00% +7.89% +1.85% -4.15% +1.16% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,23 M - -
Net income 2021 -159 M - -
Net cash position 2021 218 M - -
P/E ratio 2021 -4,26x
Yield 2021 -
Sales 2022 0,44 M - -
Net income 2022 -178 M - -
Net cash position 2022 121 M - -
P/E ratio 2022 -4,11x
Yield 2022 -
Capitalization 688 M 688 M -
EV / Sales 2021 2 072x
EV / Sales 2022 1 283x
Nbr of Employees 110
Free-Float 97,7%
More Financials
Company
Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The CompanyÔÇÖs platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The CompanyÔÇÖs early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the... 
Sector
Biotechnology & Medical Research
Calendar
09/28 | 04:00pmPresentation
More about the company
Ratings of Mersana Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MERSANA THERAPEUTICS, INC.
09/10MERSANA THERAPEUTICS : Plummets Following Interim Phase 1 Ovarian Cancer Trial Data
MT
09/10MERSANA THERAPEUTICS : UpRi Clinical Development Strategy and Interim Data from the Ovaria..
PU
09/10MERSANA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/07Mersana Therapeutics to Present at Upcoming Investor Conferences
GL
09/01MERSANA THERAPEUTICS : to Provide Update on the Progress of its UpRi Clinical Development ..
AQ
08/30MERSANA THERAPEUTICS : HC Wainwright Starts Mersana Therapeutics at Buy With $28 Price Tar..
MT
08/18MERSANA THERAPEUTICS : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/16MERSANA THERAPEUTICS : Dr. Misra to succeed Michael Kaufman, Ph.D., Chief Manufacturing Of..
PU
08/16MERSANA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disc..
AQ
08/16MERSANA THERAPEUTICS : Announces Appointment of Tushar Misra, Ph.D., as Chief Manufacturin..
AQ
08/16Mersana Therapeutics, Inc. Announces Executive Changes
CI
08/06MERSANA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/06MERSANA THERAPEUTICS' : Q2 Loss Widens, Collaboration Revenue Declines
MT
08/06MERSANA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Stat..
AQ
08/06MERSANA THERAPEUTICS : Announces Second Quarter 2021 Financial Results and Provides Busine..
AQ
More news
News in other languages on MERSANA THERAPEUTICS, INC.
09/10Mersana Therapeutics s'effondre après les résultats provisoires d'un essai de phase 1 s..
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
More news
Analyst Recommendations on MERSANA THERAPEUTICS, INC.
More recommendations
Chart MERSANA THERAPEUTICS, INC.
Duration : Period :
Mersana Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERSANA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 9,59 $
Average target price 26,67 $
Spread / Average Target 178%
EPS Revisions
Managers and Directors
Anna Protopapas President, Chief Executive Officer & Director
Brian DeSchuytner Senior Vice President-Finance & Product Strategy
David M. Mott Chairman
Timothy B. Lowinger Chief Science & Technology Officer
Donna M. Jarlenski Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
MERSANA THERAPEUTICS, INC.-63.96%688
GILEAD SCIENCES, INC.23.12%88 970
BIONTECH SE318.73%81 878
WUXI APPTEC CO., LTD.35.75%69 413
REGENERON PHARMACEUTICALS33.91%66 632
VERTEX PHARMACEUTICALS-21.38%48 168